Skip to main content

Table 2 Traditional cardiovascular risk factors and vascular parameters of patients and healthy controls

From: Small artery elasticity is decreased in patients with systemic lupus erythematosus without increased intima media thickness

 

CTL (n= 30)

SLE (n= 30)

EH (n= 20)

Age, years

42 ± 11

41 ± 10

49 ± 15

Female, n (%)

26 (87%)

26 (87%)

12 (60%)

BMI, kg/m 2

24 ± 2.6

25 ± 5.0

25 ± 3.7

Blood pressure, mmHg

   

   Systolic

120 ± 9

125 ± 17

151 ± 15**##

   Diastolic

70 ± 6

72 ± 10

88 ± 9**##

Dyslipidaemia, n (%)

14 (47%)

15 (50%)

13 (65%)

Smokers, n (%)

3 (10%)

9 (30%)*

3 (15%)#

Family history CVD, n

5 (17%)

5 (17%)

7 (35%)

HbA1c (%)

5.4 ± 0.3

5.7 ± 0.7

5.3 ± 0.4

Statins, n (%)

0

1 (3%)

3 (15%)*

Antihypertensives, n (%)

0

9 (30%)**

0

   Beta-blockers

0

4 (13%)*

0

   ACE inhibitors

0

5 (17%)*

0

   Calcium antagonists

0

1 (3%)

0

Hypertension, n (%)

0

9 (30%)**

20 (100%)**##

SAE, ml/mmHg × 100

8.1 ± 2.6

6.4 ± 2.7**

5.2 ± 3.8**

AF, AU

1.9 ± 0.4

2.1 ± 0.5*

2.3 ± 0.5**

IMT, mm

   

   Mean Maximum

0.72 (0.69 to 0.87)

0.71 (0.68 to 0.77)

0.89 (0.76 to 0.99)* ##

   Mean

0.64 (0.59 to 0.70)

0.61 (0.57 to 0.66)

0.75 (0.67 to 0.86)** ##

C-reactive protein, mg/l

0.8 (0.4 to 1.5)

1.8 (0.5 to 4.5)*

1.7 (0.5 to 2.8)

VCAM-1, ng/ml

371 ± 101

548 ± 165**

393 ± 111##

vWf, %

67 (46 to 88)

130 (89 to 223)**

78 (50 to 177)#

TM, ng/ml

1.6 (1.2 to 1.7)

1.7 (1.2 to 2.3)

1.8 (1.5 to 2.6)*

  1. Unless stated otherwise, data are expressed as mean ± standard deviation when normally distributed and as median (interquartile range) when non-normally distributed. ACE, angiotensin converting enzyme; AF, autofluorescence; AU, arbitrary units; BMI, body mass index; CrCl, creatinine clearance; CRP, C-reactive protein; CTL, healthy controls; CVD, cardiovascular disease; EH, essential hypertension patients; HbA1c, hemoglobulin A1c; IMT, intima media thickness; SAE, small artery elasticity; SLE, SLE patients; TM, thrombomodulin; VCAM-1, vascular cell adhesion molecule-1; vWf, von Willebrand factor. Patients versus controls: * P ≤ 0.05, ** P ≤ 0.01. EH patients versus SLE patients: # P ≤ 0.05, ## P ≤ 0.01.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us